Biosante Pharmaceuticals
🇨🇦Canada
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Phase 3
Completed
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Drug: placebo gel
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- BioSante Pharmaceuticals
- Target Recruit Count
- 626
- Registration Number
- NCT01235754
- Locations
- 🇺🇸
BioSante Site #101, Cleveland, Ohio, United States
🇺🇸BioSante Site #128, Seattle, Washington, United States
🇺🇸BioSante Site #024, Miami, Florida, United States
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Phase 3
Completed
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Drug: placebo gel
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- BioSante Pharmaceuticals
- Target Recruit Count
- 575
- Registration Number
- NCT00657501
- Locations
- 🇨🇦
BioSante Site #175, Vancouver, British Columbia, Canada
🇺🇸BioSante Site #045, Chicago, Illinois, United States
🇺🇸BioSante Site #149, Chicago, Illinois, United States
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
Phase 3
Completed
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Drug: placebo gel
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- BioSante Pharmaceuticals
- Target Recruit Count
- 3656
- Registration Number
- NCT00612742
- Locations
- 🇺🇸
BioSante Site 127, Billings, Montana, United States
🇨🇦BioSante Site #175, Vancouver, British Columbia, Canada
🇺🇸BioSante Site 101, Cleveland, Ohio, United States
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Phase 3
Completed
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Drug: placebo gel
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- BioSante Pharmaceuticals
- Target Recruit Count
- 597
- Registration Number
- NCT00613002
- Locations
- 🇺🇸
BioSante Site #040, Tucson, Arizona, United States
🇺🇸BioSante Site #209, Greer, South Carolina, United States
🇺🇸BioSante Site #097, Hilton Head Island, South Carolina, United States
Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms
Phase 3
Completed
- Conditions
- Hot Flashes
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2006-10-24
- Lead Sponsor
- BioSante Pharmaceuticals
- Target Recruit Count
- 431
- Registration Number
- NCT00391417
© Copyright 2025. All Rights Reserved by MedPath